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Mitochondria are vitally important organelles involved in an array of functions. The most notable is their prominent role in
energy metabolism, where they generate over 90% of our cellular energy in the form of ATP through oxidative phosphorylation.
Mitochondria are involved in various other processes including the regulation of calcium homeostasis and stress response.
Mitochondrial complex I impairment and subsequent oxidative stress have been identified as modulators of cell death in
experimental models of Parkinson’s disease (PD). Identification of specific genes which are involved in the rare familial forms
of PD has further augmented the understanding and elevated the role mitochondrial dysfunction is thought to have in disease
pathogenesis. This paper provides a review of the role mitochondria may play in idiopathic PD through the study of experimental
models and how genetic mutations influence mitochondrial activity. Recent attempts at providing neuroprotection by targeting
mitochondria are described and their progress assessed.
1. Introduction
Parkinson’s disease (PD) is a chronic, progressive neurode-
generative disorder, the second most common age-related
neurodegenerative disease after Alzheimer’s disease [1]. It
can be characterised clinically by rigidity, resting tremor,
and postural instability [2]. These symptoms result from the
loss of dopaminergic neurons in the substantia nigra pars
compacta (SNpc) and a subsequent depletion of dopamine
in the striatum [2].
The etiopathogenesis of PD is still not fully understood.
95% of cases are sporadic: a multifactorial, idiopathic
disorder resulting from contributions of environmental and
genetic susceptibility. The remaining 5% is the result of
genetic mutations, of which there are several types, many
only recently identified. However, old age remains the
greatest risk factor, with 0.3% of the entire population
aﬀected, rising to more than 1% in the over 60 s and
4% in those over the age of 80 [3]. The two forms of
PD share pathological, biochemical, and clinical features,
with dysfunction of mitochondria and associated molecular
pathways representing a bridge between the two forms of PD
as well as the natural ageing process.
Most mitochondrial dysfunction results from damage to
complex I—or NADH (nicotinamide adenine dinucleotide
phosphate):ubiquinone oxidoreductase—the first and most
complex protein in the electron transport chain [4]. It is
a large protein, consisting of 42 or 43 subunits [5] on the
inner mitochondrial membrane, which forms part of the
oxidative phosphorylation system [6]. Defects to complex I
are thought to be central to the pathogenesis of PD, and many
other known cell death pathways play a role in complex I-
mediated dopaminergic cell death, such as Bax transcription
activation [7]. Moreover, the presence of intramitochondrial
enzymes such as cytochrome c and their role in apoptosis
[8] may make mitochondria particularly vulnerable to
pathogenic events when physiological mechanisms become
disrupted. Oxidative stress can increase the releasable pool
of cytosolic cytochrome c [9]—a crucial initiator of the
caspase apoptotic signalling cascade [10]—through perox-
idation of cardiolipin [7], a mitochondrial-specific lipid.
Defects in complex I lower the threshold for Bax-mediated
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mitochondrial-dependent apoptosis [9], a crucial event in
the degeneration of dopaminergic neurons in the SNpc [11].
This advances the suggestion that mitochondrial dysfunction
is a common link and a point of convergence to diﬀerent
pathogenic pathways.
Mitochondrial dysfunction is implicated further in
sporadic PD by the finding that complex I inhibition
can decrease proteosomal activity, which in turn renders
dopaminergic neurons more susceptible to damage by some
neurotoxins [12]. This suggests that a decline in proteasomal
activity could be the mechanism by which the ubiquitin-
proteasomal system is impaired, leading to the development
of pathological protein aggregates.
The implication of mitochondrial dysfunction in PD
began with the accidental exposure of 4 Californian
drug users to 1-methyl-4-phenyl-1,2,3,6-tetrahydopyridine
(MPTP) (see [13] for a summary of the discovery). Their
intravenous administration of the meperidine analogue
resulted in selective death of cells in the substantia nigra
[14]. The toxin has now been extensively used in mice and
nonhuman primates as an experimental model for PD [1],
which has allowed the molecular basis of neuronal death to
be followed. The eﬀect is systemic, with human platelets also
vulnerable to MPP+-induced toxicity [15]. The unravelling
of the action of MPTP has led to a great deal of information
regarding the involvement of mitochondrial dysfunction.
Armed with further information regarding the molecular
pathogenesis of PD, investigators have identified further
toxins with the capacity to be used for PD experimental
models [16]. All have mitochondrial dysfunction and the
related activation of cellular pathways at the heart of their
eﬀects.
2. Mitochondrial Dysfunction in
PD and Oxidative Stress
Oxidants, including hydrogen peroxide and superoxide rad-
icals, are produced as byproducts of oxidative phosphoryla-
tion, making mitochondria the main site of ROS generation
within the cell. This is a normal situation and basal levels
of ROS can be limited by a range of antioxidants. However,
in pathological situations, where mitochondrial respiratory
defects occur, the amount of ROS produced by the elec-
tron transport chain increases dramatically, swamping the
antioxidant protection mechanisms. PD has been shown
to produce these conditions. A postmortem description of
complex I deficiency in the substantia nigra of PD patients
led to the direct link between mitochondrial dysfunction and
the disease [17], which has since been repeatedly observed
[18]. Respiratory chain defects can also be found in platelets
[19] and other highly oxidative tissues, such as skeletal
muscle [20], in idiopathic PD.
Perier et al. [9] has linked increased ROS levels to com-
plex I inhibition with the use of neurotoxin models. Complex
I defects can lower the threshold of apoptosis mediated by
mitochondria through depletion in ATP production and
the generation of free radicals [9]. Elevated ROS levels can
also result in damage to phospholipids and polyunsaturated
free fatty acids (PUFA), which are both highly prevalent in
the brain and very susceptible to oxidative damage. In PD,
lipid peroxidation is increased in the SN up to the time
of death compared to age-matched controls, as shown by
lower PUFA content—an index of the amount of available
substrate available for lipid peroxidation—in post-mortem
tissue [21]. Levels of markers of oxidative damage to proteins
are also increased in PD post-mortem tissues, with a twofold
increase in the SN [22, 23]. Two reasons are given for this
region-specific protein carbonyl rise: the symptomatic PD
treatment levodopa contributes to this oxidation [22], and
oxidative damage is higher in dopaminergic neurons [23].
Studies have sought to find if this oxidation, and subsequent
disease progress, is related to excess production of ROS or
inadequate and impaired detoxification by the endogenous
antioxidants. Analysis of superoxide dismutase (SOD) levels
show no change in SOD1 (cytosolic isoform) levels, but
there is an increase in activity of the inducible mitochondrial
isoform SOD2 [24]. This suggests that mitochondria are the
location of increased ROS production and are the site of the
first line of defence against oxidative stress.
3. Experimental Models and
Mitochondrial Dysfunction
The discovery by Langston and colleagues in 1983 that the
neurotoxin MPTP causes specific and irreversible damage
to dopaminergic neurons and generates Parkinsonian symp-
toms [14] caused a surge in activity in PD research. The use
of a reproducible model allowed for the pathogenic events to
be studied, which has led to the gradual unravelling of many
of the biochemical disturbances (although some steps remain
unknown). Several other compounds induce dopaminergic
cell death, with all aﬀecting mitochondrial physiology.
3.1. MPTP. The metabolism of MPTP occurs in a complex
and stepwise fashion [25]. As it is highly lipophilic, the
compound can rapidly (within seconds) cross the blood-
brain barrier (BBB) after systemic administration. The pro-
toxin MPTP is metabolised within the brain to the unstable
molecule 1-methyl-4-phenyl-2,3-dihydropyridinium (MP-
DP+) by monoamine oxidase (MAO), specifically the MAO-
B subtype enzyme within nondopaminergic neurons due to
the cellular localisation of the enzyme [26]. Then, probably
due to spontaneous oxidation, it forms the active toxin
1-methyl-4-phenylpyridinium (MPP+) [27]. MPP+ is then
released via an unknown mechanism into the extracellular
space. It is the next step which accounts for the selectivity
of the toxin: as MPP+ is a polar molecule it cannot freely
enter cells, unlike its precursor, MPTP. The toxin does
however have a high aﬃnity for plasma membrane dopamine
transporter (DAT), as the use of DAT inhibitors [28, 29] or
the absence of DATs [30] prevent its uptake. Once inside
dopaminergic neurons, there are at least three routes which
MPP+ can take [31]: it can take the vesicular pathway, bind
to vesicular monoamine transporters and translocate MPP+
into synaptosomal vesicles [32]; it can interact with various
cytosolic enzymes by remaining in the cytosol [33], or can be
concentrated within the mitochondria [34]. The eﬀect of the
latter of these three routes will now be discussed. However,
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it should be noted that a cascade of deleterious eﬀects [31]
contribute to a greater or lesser extent to dopaminergic
cell death, and no factor alone is the sole cause of the
degeneration.
MPP+ enters the mitochondria passively due to the large
transmembrane potential of mitochondrial membranes and
accumulates at the matrix. The levels of MPP+ in the mito-
chondria can reach saturation within a few minutes [34]. The
rate of the toxin’s uptake depends on its intramitochondrial
concentration, which inversely aﬀects the transmembrane
potential [34]. This equilibrium is disrupted when mito-
chondria become anaerobic or the transmembrane potential
gradient is disturbed by the presence of an uncoupling agent
[34].
Once MPP+ has entered the mitochondria in this potent
and rapid manner, the toxin can aﬀect various functional
elements of the organelles. For example, the tricarboxylic
acid cycle enzyme α-ketoglutarate dehydrogenase is inhibited
by MPP+ [35]. But the main cause of mitochondrial
dysfunction involves the compound’s action on complex I of
the respiratory chain. MPP+ binds to complex I soon after
its uptake by dopaminergic neurons. Rotenone (discussed
below) is a classic complex I inhibitor. Its binding is blocked
by the presence of MPP+ [36], confirming the site of the
toxin’s action. It has been found that the binding of MPP+
is required at two distinct sites (one hydrophilic and one
hydrophobic) for complete NADH inhibition, but it provides
a much weaker inhibition of complex I than rotenone
[4, 37]. The binding to the first of these sites aﬀects the
coupling between the PSST and NADH dehydrogenase (ND)
1 subunits (20 and 36 kD, resp.) of complex I, while the
location of the second site, although apparently causing
a more potent a more potent inhibition of complex I
enzymatic activity [4], is not precisely known. The flow
of electrons is interrupted in a dose- and time-dependent
manner, leading to an acute deficit in ATP production,
particularly in the striatum and ventral midbrain [38, 39].
However, due to the low levels (around 20%) of ATP
depletion which actually occurs in vivo in whole mice
brain tissues [38] and the evidence that there is little or
no neuronal loss when residual ATP levels are maintained
above 20% [11], there is thought to be more prominent
factors causing MPTP-induced dopaminergic cell death than
a MPP+-related reduction in ATP levels. In addition to this,
complex I activity is required to be reduced by more than
50% to cause significant ATP depletion [40]. The role of
complex I inhibition in MPP+ toxicity is further questioned
by Choi et al. [41], who found the toxin caused dopaminergic
cell death occurred despite a lack of the Ndufs4 gene, essential
for complex I assembly and function. The importance of
MPP+ binding can be supported, however, by improvements
in ATP production and alleviation of degeneration after
eﬀorts to stimulate mitochondrial respiration by way of a
bypassing of the complex I blockade [42].
Mitochondria are a major source of ROS, with up to 2%
of all oxygen consumed by mitochondria being converted
to superoxide [43]. The production of ROS is increased
after MPP+ inhibition of complex I [32] by more than
40% over control levels [11], which works in parallel with
other reactive molecules including nitric oxide, a molecule
produced by the nitric oxide synthase enzyme in the brain
[44]. Transgenic mice with increased brain activity of the
scavenging enzyme SOD showed resistance to MPP+ toxicity
[45]. This protective eﬀect did not aﬀect the block on
complex I activity, showing the importance and potency of
free radical damage in the MPTP model. This enzyme has
been localised in the intramembrane space where it acts
as a physiological protective mechanism against superoxide
toxicity [46]. The deleterious impact of ROS in the MPTP
model mirrors the results of studies conducted on human
post-mortem samples [47]. It is likely that a depletion of
ATP and increased ROS production, following complex I
impairment, trigger molecular cell death pathways such
the activation of procell death protein Bax [7], and it is
these ROS-initiated pathways, rather than an acute energy
shortage, which result in the greatest proportion of MPTP-
induced degeneration.
It has been proposed that MPTP may also cause
dopaminergic cell death through a reduction in the num-
ber of lysosomes [48], cytoplasmic organelles containing
hydrolytic enzymes important in the degradation of cyto-
plasmic proteins, and other organelles through the process
of macrophagy [49] (also see mitophagy, which is discussed
in Section 5.3). ROS, levels of which are elevated due
to mitochondrial dysfunction, cause permeabilisation of
lysosomes leading to defective clearance and accumulation
of the double-bonded sequesters of the cytosolic material to
be degraded, autophagosomes (APs). Lysosomal depletion
and neurodegeneration subsequently occur after ectopic
release of lysosomal proteases. Induction of lysosomal bio-
genesis attenuated the MPTP-induced cell death [48], while
rapamycin, an inhibitor of the cellular kinase mammalian
target of rapamycin (mTOR) known to induce autophagy,
can restore lysosomal levels and reduce AP accumulation
[48, 50]. This represents a further pathway by which ROS
released in energy-deprived cells cause cell death in this
model.
3.2. Rotenone. Rotenone is used commonly as a pesticide in
the UK and United States. Its use in South America dates
back to the 17th century as an agent to paralyse and surface
fish. Epidemiological studies have established a link between
contact with pesticides and an increased risk of Parkinson’s
[51], although the short half-life of the compound, partic-
ularly in sunlight (1–3 days), and the fact that it does not
leach from soils mean the chance of PD being caused directly
from environmental exposure to this pesticide is very low,
with others leading to the aforementioned epidemiological
trend [52]. Rotenone is a specific inhibitor of complex I and
causes its deleterious eﬀects through oxidative damage, with
only mild depletion of ATP levels [53]. This toxicity can
be prevented with the administration of antioxidants [53].
Rotenone rapidly crosses the BBB thanks to its lipophilic
structure, with maximal CNS concentrations reached within
just 15 minutes [54]. Within cells, rotenone freely crosses
into subcellular compartments including mitochondria, in
which the toxin impairs oxidative phosphorylation by bind-
ing to the PSST subunit of complex I [4]. Interestingly,
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due to this promiscuous manner of cell entry, rotenone
does not concentrate within dopaminergic cells selectively,
unlike MPTP, although cell death is specific to these cells.
Therefore, dopamine cells appear to be particularly sensitive
to the resultant complex I dysfunction [55]. Again unlike
MPTP, rotenone leads to the presence of Lewy bodies [56],
the proteinaceous pathologic biomarker of sporadic PD.
These inclusions are immunoreactive to α-synuclein and
ubiquitin [56]. The evidence that rotenone, a classic complex
I inhibitor, causes aggregation of Lewy bodies may mean that
mitochondrial dysfunction has a role in the development of
these pathologic protein inclusions in PD [57]. Furthermore,
recent evidence shows that rapamycin protects against
rotenone-induced apoptosis by the induction of autophagy
in SH-SY5Y human neuroblastoma cells [58]. This provides
a further link between mitochondrial dysfunction and the
toxic eﬀect of rotenone, with the clearance of the impaired
organelles induced by rapamycin preventing increases in
cytochrome c levels and apoptotic pathways [58].
3.3. 6-OHDA. 6-hydroxydopamine (6-OHDA) is a hydrox-
ylated analogue of dopamine, first isolated in 1959 [59].
It has been used most extensively in rodents. By virtue of
its structure, 6-OHDA possesses a high aﬃnity for many
catecholamine membrane transporters including DAT and
norepinephrine transporters, allowing the compound to
freely enter both dopaminergic and noradrenergic neurons
[16]. This leads to a lack of specificity, as damage can
be caused centrally and peripherally to these signalling
pathways. Therefore, administration needs to be precise:
stereotaxic injection is usually the route used to create a
Parkinsonian lesion (6-OHDA does not cross the BBB well
spontaneously, thus systemic administration does not result
in the accumulation of neurotoxic concentrations), which
represents a technical challenge. Once in catecholamine
cells, 6-OHDA causes damage through reactive oxygen
species and quinones [60]. The fine molecular details of
neuronal death are more diﬃcult to understand with this
model, however, as the ways by which cytotoxic events
occur may diﬀer depending upon the distance between
them and the site of injection [16]. Despite this, some of
these details have begun to be uncovered, including the
induction of autophagy through activation of extracellular
signal-regulated kinase (ERK) 1/2 [61, 62]. Inhibition of
the ERK pathway confers neuroprotection in 6-OHDA-
treated cells [62]. The mitochondrial localisation of ERK2
in particular causes enhanced autophagy to levels which
cause a pathologic reduction in ATP production due to
the degradation of healthy mitochondria [61], providing a
molecular component in 6-OHDA cytotoxicity.
4. Mitochondrial DNA
An extra level of complexity is added to mitochondria as
they can house their own mitochondrial DNA (mtDNA),
possibly due to an ancestry to free-living bacteria that
became trapped to form eukaryotic cells [63]. This confers
an extent of genomic autonomy to these organelles, but given
their precarious yet vital position and specific vulnerability
to toxins, it may increase the likelihood of pathogenic
alterations occurring. Mitochondrial DNA is prone to point
mutations at a higher frequency than DNA in other parts of
the genome. This is due to a lack of repair mechanism, small
mitochondrial genome size (around 16 kb in length), and the
close proximity of the genome to the site of ROS production
at the inner mitochondrial membrane. Consequently, an
accumulation of mtDNA mutations occurs throughout life
and results in precipitation of pathological disorders due to
a gradual degradation of mitochondrial eﬃciency [64–66].
As PD development is intrinsically linked with age, this is
an attractive hypothesis to couple with what is known about
the disorder’s pathogenesis. There have been various reports
to back this up [67, 68], although no single gene defect
appears likely to cause more damage than others, with gene
mutations combining in a complex manner [69]. However,
the role of mitochondrial point mutations in ageing has been
questioned by Vermulst et al. [70], who found that mutation
frequency was 11-times lower than previously reported [71]
and did not have an eﬀect on ageing in wild-type mice. The
group also debated the validity of previous data on the basis
of the PCR and cloning strategies used, techniques that are
limited by polymerase infidelity and cloning artefacts. In
another contradiction to the link between mtDNA defects
and age, a higher rate of homoplasmic mtDNA mutations
has been found in PD patients from younger subjects, who
have had less significant SN dopaminergic loss (M.F. Beal,
unpublished findings, cited in Banerjee et al. [72]). Thus, the
correlation between mtDNA damage, age, and PD incidence
is by no means indivisible.
Most neuropathological studies have been limited to
skeletal muscle, which provides an accessible tissue, impor-
tant in the diagnosis of mtDNA disorders and often involves
functional muscle impairment. Muscle from these patients
has been found to feature respiratory chain-deficient muscle
fibres. These particular fibres showed higher levels of mtDNA
deletion than normal fibres. Muscle specific mtDNA muta-
tions were found in this postmitotic tissue, demonstrating
the propensity mtDNA has to mutate and for these point
mutations to accumulate [73]. Mitochondrial proliferation
is linked to apoptosis and a high amount of mutations [74].
It has been found that complex I defects (a 25% defi-
ciency was shown) from PD patients can be transferred into
mitochondrial deficient platelet cybrids [75]. These defects
can aﬀect calcium homeostasis by altering mitochondrial
membrane potential, an elevation of ROS production and
reduced ATP production [76]. Since mtDNA encodes 7 of
the 49 protein subunits of the complex I enzyme, it is fair
to surmise that any defects to this genomic structure would
have palpable functional disturbances.
The SN may be particularly susceptible to the accumu-
lation with age of somatic mtDNA mutations due to their
age-related loss, high oxidative capacity, and sensitivity to
mitochondrial dysfunction [77]. Indeed, this group show
high levels of mtDNA deletions associated with decreased
cytochrome oxidase activity in SN neurons of both aged and
PD patients and demonstrated mitochondrial respiratory
chain impairment. Mitochondrial DNA deletions of over
43% and 52% of total mtDNA in individuals over the age
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of 70 and in PD patients, respectively, were found [77].
This data, combined with that of the independent study
carried out by Kraytsberg et al. [71] show that parkinsonism
enhances the impairments already suﬀered by aged SN
neurons due to mtDNA damage. However, despite this
correlation, it is not clear whether mtDNA mutations are
the primary cause of mitochondrial dysfunction or exist
secondary to the organelle’s functional impairment. Reeve
et al. [78] outlines the hypothesis that somatic mtDNA
mutations occur as a result of oxidative stress and clonally
expand. Cells aﬀected by PD (i.e., neurons in the SN) are
more likely to contain mtDNA mutations due to the stresses
that these cells are subject to. This provides a composite
conclusion of both schools of thought, whereby mtDNA
mutations are originally secondary to the primary cause of
disease and/or cellular stress, but once clonally expanded can
contribute to the pathogenesis of the disease by participating
in cell death pathways.
Outside of a role in conferring functional deficits, human
mtDNA exhibits region-specific variation in indigenous pop-
ulations, allowing these haplogroups to be phylogenetically
organised. Geographical-dependent replacement mutations
and amino acid conservation substitutions have allowed our
ancestors to survive more northern climates and higher
altitudes [79]. This has consequences in health today, with
some mtDNA haplotypes influencing PD expression. Van der
Walt et al. [80] found a single-nucleotide polymorphism at
10398G in individuals classed as haplogroup J, which confers
neuroprotection, particularly in women. The haplotype
causes an amino acid change from threonine to alanine in the
ND3 subunit of complex I [80]. A disease-specific link with
the mtDNA cluster UKJT has also been found and is reported
to cause a 22% reduction in population-attributable risk for
PD [81]. In a study of a Finnish population, an excess of
nonsynonomous substitutions to complex I genes in mtDNA
in the JTIWX supercluster increased the risk of PD and PD
with dementia by 2.5-fold. This supports the theory that the
total number of substitutions in mtDNA conveys the risk of
PD rather than individual mutations [82].
5. Genetic Causes of PD and Mitochondria
Heritable cases of PD make up a very small proportion of
PD cases, but a heritable factor may predispose an individual
to the development of the disease [83] and are involved in
early onset forms of the disorder [84–86]. As discussed so
far, mitochondrial dysfunction is central to the pathogenesis
of PD, thus it follows that the gene defects outlined here also
directly or indirectly aﬀect mitochondrial function.
5.1. α-Synuclein. This soluble, acidic, presynaptic nerve
terminal protein has an increased tendency to aggregate
due to its hydrophobic non-β-amyloid domain, and forms
the major structural component of Lewy bodies, as well
as acting as the precursor protein for amyloid plaques in
Alzheimer’s disease [87]. Physiologically in the substantia
nigra, it may have a role in the filling and refilling of
synaptic vesicles [88]. Three missense mutations, A53T [89],
A30P [90] and E46K [91], and one triplication [92] of
this 140-amino acid protein have so far been found to
cause an autosomal dominant inherited form of PD. It
has been discovered in yeast that functional mitochondrial
DNA is essential for α-synuclein toxicity [93]. Evidence also
suggests a role for α-synuclein in causing mitochondrial
dysfunction. A study of the A53T transgenic mouse, in
which the polymerisation process which ultimately converts
monomers into amyloid fibrils is accelerated, established
that these mice develop dysmorphic mitochondria in brain
stem and spinal cord cells [94]. It has also been found
in vitro that overexpression of α-synuclein impairs mito-
chondria structure and function [95]. In addition to this,
cytochrome c interacts with mitochondria in Lewy bodies
to promote their aggregation [96], as well as activating cell
death pathways. Mitochondrial DNA damage was also found
in A53T mice, while nuclear DNA remained intact [94],
demonstrating the increased vulnerability of mtDNA. Wild-
type α-synuclein is protective and lowers staurosporine-
induced caspase-3 activity and p53 expression [97], but these
eﬀects can be reversed by the addition of 6-OHDA, thus
shifting this antiapoptotic protective function to one which
contributes to the aggregation of α-synuclein [98], suggesting
an indirect mechanism by which mitochondria interact
with cell death pathways. Mutant α-synuclein expression
in vitro show reduced proteasomal activity without direct
toxicity, although they were more sensitive to apoptotic-
mediated cell death along with mitochondrial depolarisation
and caspase-3 and -9 elevation when treated with subtoxic
concentrations of a proteasomal inhibitor [99], linking the
paths of mitochondrial dysfunction and protein aggregation.
But it remains unclear whether mitochondrial dysfunction
precedes α-synuclein inclusion formation or vice versa.
They are, however, intrinsically linked. α-synuclein asso-
ciates with mitochondria during pathologic conditions: a
sequence in the N-terminal of human protein contains
a mitochondrial-targeting signal that leads to α-synuclein
associating with the inner membrane of the mitochondria,
resulting in complex I impairment and increased ROS
production [100], increased protein tyrosine nitration and
a decreased mitochondrial transmembrane potential [101].
The cell death pathway mediator, cytochrome c, is also
released upon this aggregation [102]. The association of
α-synuclein and mitochondria was especially significant in
PD-vulnerable brain regions, that is, SNpc and striatum
[100]. Rotenone-induced aggregation of α-synuclein, and
the subsequent decrease in ATP levels, was reversed by the
removal of the complex I inhibitor [103], highlighting the
importance of mitochondrial impairment to aggregate for-
mation. The possibility that the combination of α-synuclein
and mitochondria is a protective measure can be countered
by evidence that α-synuclein-null mice are resistant to mito-
chondrial toxins, including MPTP [104, 105]. It has been
suggested that abnormal cytosolic conditions are required
for this signalling to become active and translocation to
take place: it occurs rapidly in low intracellular pH [106],
a condition which may be caused by ROS overproduc-
tion and metabolic stress. Thus, biochemical abnormalities
interact with genetic modifications to the α-synuclein gene
resulting in the impairment of mitochondrial function and
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subsequent neuronal degeneration. These interactions are
demonstrated in Figure 1.
5.2. Parkin. Mutations to the parkin gene (PARK2) are
linked to an autosomal recessive juvenile form of the disease
[107], constituting the most common cause of young onset
PD. Hundreds of such cases have been found in patients
from almost all ethnic backgrounds [108]. The parkin
gene encodes a 465 amino acid RING finger-containing
protein. Like other RING finger proteins, parkin acts as
a ubiquitin E3 ligase. It has an important role in the
function of ubiquitin, which is primarily involved in the
targeting of aggregation-prone substrates for degradation
by proteosomes, by conferring substrate specificity (parkin’s
function is reviewed [109]). This function has been shown
in vitro [110]. Thus, mutations to parkin may cause loss
of this ligase activity resulting in accumulation of toxic
substrates and degeneration, with many potential substrates
for parkin [109]. The fact that these substrates do not fit into
a common pathway may be due to the broad range of reg-
ulatory functions, alongside protein aggregate degradation,
which ubiquitin fulfils. These include signal transduction,
postreplicative DNA repair, endocytosis protein traﬃcking,
and regulation of transcription and translation [111].
But parkin’s most reproducible, and possibly most rele-
vant, activity is its neuroprotective activity against a variety
of pathogenic factors. At least, some of this neuroprotection
is aﬀorded by delaying mitochondrial swelling and rupture
and the subsequent cytochrome c release and caspase-3
activation, as demonstrated in cells overproducing parkin
[112]. The importance of parkin in the normal function of
mitochondria as a controller of cytochrome c release, and
therefore apoptosis, is underlined by the inverse relationship
expression levels of parkin share with cytochrome c release
[113]. Parkin can become associated with the mitochondria,
particularly the outer membrane, suggesting a direct and
local protective eﬀect [114]. The protein is involved with
the regulation of transcription and replication of mitochon-
drial DNA in proliferating cells, stimulating the organelle’s
biogenesis—an eﬀect blocked by parkin short-interfering
RNA (siRNA) knockdown [114]. This has been backed-
up in vivo: parkin-null mice show reduced mitochondrial
respiratory capacity as well as increased protein and lipid
peroxidation [115] leading to nigrostriatal defects but not
loss of dopaminergic neurons [116]. Mitochondrial mor-
phological changes have been observed, but this led only to
disruption of complex I function in nigral mitochondria and
did not result in cell death [117]. Abnormal morphological
branching of mitochondria and lowered complex I-mediated
ATP production have been described in parkin-mutant
fibroblasts, but these functional impairments did not occur
when parkin was knocked down by 50% [118]. An increased
susceptibility to oxygen radical damage has been observed
in parkin-null Drosophila [119]. A comprehensive study
has confirmed the association between parkin and mtDNA,
leading to protection from oxidative stress and stimulation
of mitochondrial genome damage [120]. These functions
were impaired in parkin-deleted human fibroblasts [120].
Thus, functional parkin is important in the maintenance
of mitochondrial antioxidant defences and protection of
mtDNA.
5.3. PINK-1. PINK1 (PTEN-induced putative kinase 1) gene
mutations are the second most common cause of autosomal
recessive, early-onset parkinsonism [86]. This 581 amino
acid protein features a serine/threonine kinase domain,
which is the site of most missense mutations, leading to
impairment of kinase activity [86]. Like parkin, PINK-1
has been shown to be protective in a number of stress
paradigms [121–123]. Nigrostriatal neuronal loss has been
observed in post-mortem brains of PD patients with PINK1
mutations [124]. This study also showed the localisation of
PINK1 to mitochondria. It is here that PINK1 mutations
are thought to cause PD by impaired phosphorylation of its
substrates, although the precise mitochondrial location of
PINK1 association is unclear [125].
Mutations of PINK1 result in a loss of the protein’s
function, leading to PD. It is in mitochondria that the
impaired phosphorylation is most deleterious: mitochon-
drial cristae are fragmented in PINK1 mutants, and there
is increased susceptibility to oxidative stress [126]. PINK1
mutants share many phenotypic characteristics with parkin
mutants [127, 128]. It could then be delineated that the two
proteins act in a common pathway, with parkin functioning
downstream of PINK1, as transgenic expression of parkin
ameliorated all PINK1 impairments, but not vice versa [127–
129]. Further interplay between these proteins has recently
been uncovered (see Figure 2). Recent evidence has suggested
that PINK1 along with parkin has a role in the mitochondrial
targeting of autophagy, a process by which cells degrade
intracellular material via the employment of lysosomes
[130]. Mitophagy, the mitochondrial-specific form of the
process, is important in the disposal of damaged or stressed
organelles. The process is upregulated after disturbances in
mitochondrial membrane permeability (reviewed in [131]).
Accumulation of mutated α-synuclein protein also initiates
this compensatory mechanism [132] (although parts of the
autophagic-lysomal system may be impaired in these cases,
as levels of the lysosomal protease cathepsin D are reduced
[133, 134]). Parkin is selectively recruited from the cytosol to
mitochondria with low membrane potential, where the pro-
tein mediates the degradation of the dysfunctional organelle
(induced in this study using the uncoupler carbonyl cyanide
m-chlorophenylhydrazone (CCCP)) by lysosomes [135].
PINK1 acts as the biochemical signal allowing parkin to
identify dysfunctional mitochondria, the levels of which are
regulated by voltage-dependent proteolysis [136]. The E3
ligase function of parkin, which is constitutively repressed,
becomes activated upon PINK1-dependent mitochondrial
localisation [137]. Thus, defective mitophagy due to a lack of
parkin recruitment to dysfunctional mitochondria by PINK1
causes the accumulation of impaired mitochondria, and a
subsequent buildup of ROS and proapoptotic proteins. The
importance of this system is furthered by the evidence that
VPS41, a protein known to traﬃc proteins to lysosomes in
yeast, is neuroprotective in 6-OHDA and rotenone cellular
models by blocking the apoptotic cascade and enhancing
protein clearance, although the toxin-induced mitochondrial
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Figure 1: Genetic mutation of α-synuclein and subsequent protein and biochemical alterations. Modifications to the α-synuclein gene cause
dysfunction of its protein product. Proteasomal activity becomes impaired, leading to an increased tendency for the protein to aggregate.
Mutated α-synuclein protein also localises at the inner mitochondrial membrane, causing complex I dysfunction. ATP production is
subsequently reduced, as is the transmembrane potential of the organelle. Increased levels of ROS result, and with mtDNA being particularly
susceptible to ROS damage, further cell stress occurs. The acidic cytosolic environment created by ROS and metabolic impairment results in
the activation of cell death mediators, such as cytochrome c. Apoptotic pathways are initiated and cell death subsequently occurs.
membrane potential disruption was not aﬀected [138].
Vives-Bauza et al. [139] expands upon the functions of
parkin and PINK1 by describing a role in mitochondrial
traﬃcking to the perinuclear region—a subcellular area asso-
ciated with autophagy, again suggesting the proteins function
in mitochondrial turnover. These functions are repressed
in knockout models of the two proteins involved, implying
that a lack of these events play a role in pathogenesis.
Moreover, overexpression of parkin enhanced the protective
eﬀects of mitophagy, with autophagy proteins such as Atg7
and LC3/Atg8 involved in mitochondria remodelling [140].
This provides a link between morphology and some active
processes of mitochondria which impact upon cell survival.
Morphological changes of the tubular networks which
mitochondria form impact cell survival, with a balance
between the processes of fission and fusion required to
maintain morphological integrity. Mitochondria are highly
dynamic organelles, and these processes are ongoing. It
has been found that overexpression of PINK1 promotes
mitochondrial fission while inhibition of the protein causes
excessive fusion [141, 142]. The PINK1/parkin pathway thus
achieves its eﬀect of mitochondrial integrity by promoting
fission [142, 143]. Ageing aﬀects mitochondrial activity and
how it reacts to a lack of PINK1: at 3-4 months, impaired
mitochondrial function after PINK1 knockout was observed
in the striatum but not in the cerebral cortex; however, at
2 years of age, this impairment also occurred in the cortex
[144]. Impairments to mitochondrial respiration in this
study were induced by cellular stress-mediators, as well as a
reduction in the activity of the Kreb’s cycle enzyme aconitase,
underlining the protein’s protective role in mitochondria to
intrinsic and extrinsic factors. Examination of fibroblasts
from a patient aﬀected by a PINK1 mutation has revealed
low mitochondrial respiratory activity and enhanced oxygen
radical production due to complex I inhibition [145],
demonstrating clinically the eﬀects found experimentally.
5.4. DJ-1. A rarer cause of early-onset forms of PD is
mutations to the gene encoding the 189-amino acid protein,
DJ-1. Aﬀecting the PARK7 gene, they account for 1-2%
of these cases [85]. As with the other proteins outlined,
mutant studies demonstrate an increased susceptibility to
cell death. Knockdown of DJ-1 by siRNA led to populations
of the human neuroblastoma cell line SH-SY5Y becoming
susceptible to several oxidative insults including hydrogen
peroxide, MPP+ and 6-OHDA [146]. Conversely, DJ-1
overexpression in this cell line leads to increased resistance
to these insults and reduced intracellular ROS levels [147].
This protection is apparently selective against environmental
oxidative stress in vivo, as shown in the paraquat-treated DJ-
1-null Drosophila model [148]. Furthermore, the levels of
DJ-1 modification increase with age, leading to significant
increases in oxidative stress and inactivation of the protein’s
function [149]. This shows that DJ-1 modifications may have
a role in sporadic PD in aged animals, in addition to familial
early-onset cases. DJ-1-deficient mice show hypersensitivity
to MPTP—manifested by increased dopaminergic neuronal
loss and striatal denervation [150]. Embryonic cortical
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Figure 2: The physiological association of parkin and PINK1 proteins in mitophagy. (1) Genetic mutations or the introduction of toxins
lead to various impairments, including depletion of ATP production at the electron transfer chain. A buildup of ROS leads to a more acidic
environment within the mitochondrion, as well as inducing a decrease in the mitochondrial transmembrane potential after the opening
of permeability transition pores. This is the signal for mitophagy to occur. (2) The process is induced through the interaction of cytosolic
parkin with mitochondria-associated PINK1. PINK1 acts as the biochemical signal for parkin to identify damaged mitochondria. (3) Parkin
then mediates the lysosomal degradation of the dysfunctional organelle.
neurons have shown increased sensitivity to oxidative stress
[150] and proteasomal inhibition leading to apoptosis [151].
All impairments were reversed by restoration of DJ-1 expres-
sion [150]. DJ-1 is activated by an oxidative cytoplasmic
environment [152], thus its protective mechanism works
in an on-demand manner. This group describe a role
for DJ-1 as a redox-sensitive molecular chaperone, which
inhibits α-synuclein aggregate formation. The complex I
inhibitor paraquat decreased proteasome activity along with
ATP and regulatory subunit levels in DJ-1 deficient mice,
but not wild-type littermates [153]. In addition to this, a
transcription factor, expression nuclear factor erythroid 2-
related factor 2 (Nrf2), which induces cytoprotective genes,
was reduced. This provides evidence that DJ-1 acts as a
regulator of transcription. The mechanism by which DJ-
1 protects against oxidative stress has been investigated:
the protein has been shown to regulate the MAP3 kinase
apoptosis signalling-regulating kinase 1 (ASK1)/thioredoxin
1 (Trx1) complex [154]. ASK1 is a major eﬀector of oxidative
cell death and is physiologically inhibited by Trx1. The
association is disrupted by oxidative stimuli, and DJ-1-null
cells are more susceptible to this dissociation, leading to
increased activation of downstream cell death mediators.
It has been shown that DJ-1 does not take part in the
PINK1/parkin pathway, as overexpression of DJ-1 could not
reverse the PINK1 inactivation phenotype [128].
A direct mitochondrial-DJ-1 association has been uncov-
ered. Lev et al. [147] described a cellular redistribution of DJ-
1 when cells were exposed to neurotoxins. This is expanded
upon by Hayashi et al. [155] who show DJ-1 binding
to NADH dehydrogenase (ubiquinone) 1 α-subcomplex 4
(NDUFA4) and ND1, nuclear and mitochondrial DNA-
encoding subunits of complex I, demonstrating the impor-
tance of DJ-1 in mitochondrial activity. Mitochondrial DJ-1
acts as an atypical peroxiredoxin-like peroxidise, as indicated
by the twofold increase in mitochondrial hydrogen peroxide
levels in DJ-1 knock-out mice. Cysteine-106 forms the site
of the oxidation required for scavenging hydrogen peroxide
[156], and potentially other ROS.
5.5. LRRK2. Mutations to the leucine-rich repeat kinase 2
(LRRK2) gene cause a form of autosomal dominant PD.
The mutations are associated with familial late-onset PD
as well as some sporadic cases of the disorder, which has
increased the interest in this gene [157]. The LRRK2 gene
encodes a large 2527 amino acid multidomain protein, the
physiological function of which is currently unknown. But
there are numerous functional domains associated with the
protein, including GTPase [158] and kinase domains [157],
implying an array of roles. LRRK2 is present largely in
the cytoplasm but also associates with the outer membrane
of mitochondria [159, 160], suggesting a role in this
organelle. However, the role of LRRK2 in PD pathogenesis
is questioned by Andres-Mateos et al. [161], who find a
sensitivity to MPTP insult of LRRK2 knock-out mice in
line with wild-type mice (in contrast to other established
gene defects), as well as normal dopaminergic signalling
and cell survival levels. Most of the accumulated evidence
suggests that a gain-of-function defect causes PD pathology,
with an increase in kinase activity prominent in disease
development [160, 162]. It has been found by Lin et al.
[163] that LRRK2 mutations accelerate the progression of
neuropathological abnormalities in α-synuclein transgenic
A53T mice by promoting the aggregation of the α-synuclein.
These eﬀects are thought to be due to induction of the
LRRK2 protein’s kinase domain, causing activation of the
ERK module [164]. Genetic ablation of LRRK2 in mice
had converse eﬀects, suppressing aggregation and delaying
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the development of PD-related pathology [163] as did
pharmacological inhibition of ERK in vitro [164]. However,
LRRK2 ablation does not appear to be a viable clinical
treatment option. The dopaminergic system of LRRK-null
mice appears normal, but it is in the kidneys where the loss
of the gene has greatest impact, with a 60-fold increase in
the accumulation of α-synuclein and ubiquitinated proteins
in aged animals [165]. LRRK2 loss leads to inflammatory
responses, oxidative damage and apoptotic cell death [165],
meaning mitochondria may be aﬀected. However, this
toxicity induced by oxidative stress has been mapped to be
caused by the kinase domain, and ERK inhibition restored
cell survival to near-control levels [166]. Therefore, it appears
that mitochondria play a relatively minor role in LRRK2-
related pathology compared to in other gene defects—as
demonstrated convincingly by the lack of hypersensitivity
to MPTP [161]—with the activity of kinase pathways more
involved.
6. Neuroprotective Methods Targeting
Mitochondrial Dysfunction
Given their position at the centre of a web of cellular
functions and pathways and their role in both idiopathic
and familial PD, mitochondria constitute a popular target in
eﬀorts to protect dopaminergic neurons, thereby arresting
degeneration and maintaining the functional capacity of
patients.
6.1. Coenzyme Q10. The most well-known mitochondrial-
targeting neuroprotective agent is coenzyme Q10 (also
known as ubiquinone). The structure functions primarily
as an electron acceptor in the electron transport chain—
shuttling electrons between complexes I and II/III—and a
potent antioxidant. It can prevent apoptosis by blocking
both the binding of Bax to mitochondrial membranes and
cytochrome c release [167] and inhibiting the opening of
the Ca2+-gated mitochondrial permeability transition pore
(PTP) and the subsequent apoptotic pathway activation
[168]. Coenzyme Q10 can directly scavenge free radicals
in the inner mitochondrial membrane through interactions
with α-tocopherol [169]. Reduced levels of coenzyme Q10 in
mitochondria isolated from PD patients were found [170],
as well as a lower serum level of the enzyme in patients
with Parkinsonism compared to stroke patients of similar
age [171], which showed the potential supplementation of
this agent could have. Treatment with diﬀerentiated human
neuroblastoma cells showed inhibited ROS formation and
cell death induced by the herbicide paraquat in repose
to coenzyme Q10 [172], while pretreated rat mesenphalic
cells were protected against rotenone-induced apoptosis and
mitochondrial depolarisation [173]. Preclinical in vivo stud-
ies augmented this theory with evidence that oral supple-
mentation with coenzyme Q10 reduced striatal dopaminer-
gic neuronal loss in MPTP-treated mice [174] and protected
against 3-nitroproprionic acid striatal lesions in rats [175]. A
clinical trial used a double-blind, placebo-controlled design,
and randomly assigned placebo or coenzyme Q10 at doses of
200, 600 or 1200 mg per day to a total of 80 patients with early
PD [176]. Patients were rated on the Unified Parkinson’s
Disease Rating Scale (UPDRS) over a period of 16 months.
Coenzyme Q10 was safe and well tolerated at all dose levels,
with the group receiving the highest dose developing PD
symptoms at the slowest rate—a slowing a 44%. However,
in a study of 130 patients receiving a daily dosage of 300 mg,
which led to coenzyme Q10 plasma levels of 1200 mg, the
agent had no symptomatic eﬀect [177]. Therefore, despite
mixed results from clinical trials, a strong body of evidence
exists to merit further investigation into the therapeutic
eﬀects of coenzyme Q10 in PD. A large phase III clinical trial
following patients for 16 months is due to be completed in
2011. This study will compare the eﬀects of doses of 1200 and
2400 mg per day and placebo in 600 early stage PD patients
[178].
6.2. Creatine. Creatine, a nitrogenous guanisine compound,
is another potential mitochondria-targeting treatment that
has been investigated to clinical trial level. It occurs nat-
urally in vertebrates (produced endogenously by the liver,
kidneys, and pancreas) and helps supply energy to muscle
and neurons via its conversion to phosphocreatine. This
structure can transfer its phosphoryl group to ADP, thereby
creating ATP. This reaction is important in maintaining
a ready subcellular supply of ATP. Additional supplies of
this compound may be especially valuable during times of
cellular stress and dysfunction when energy production is
compromised. The addition of creatine has been shown to be
useful in a number of models of neurodegenerative diseases,
including amytrophic lateral sclerosis [179], Alzheimer’s
disease [180], and Huntington’s disease [181]. In vitro
results show significant neuroprotection of dopaminergic
cell numbers and morphology against MPP+ and 6-OHDA
exposure [182]. Oral administration of creatine can protect
against MPTP-induced dopaminergic cell loss in mice in
a dose-dependent manner [183]; this neuroprotection can
be augmented with the addition of the cyclooxygenase-
2 inhibitor rofecoxib [184]. The long-term (i.e., 2 years)
safety of creatine supplementation has been tested in 60
aged PD patients and approved as safe, but the potential
risk to patients with underlying renal problems has been
identified [185]. However, a blinded, placebo-controlled
clinical trial showed no significant diﬀerence in the UPDRS
scores of 31 patients with PD compared to the 17 placebo-
treated volunteers after 18 months of treatment [186]. But
the test did show a lower requirement for symptomatic
treatment in the patients who received creatine, which may
represent a degree of dopaminergic signalling protection.
This success, however limited, has led to a phase III clinical
trial being announced [187]. In addition to monotherapy,
a combination of creatine and coenzyme Q10 was found
to exert synergistic protective benefits against dopamine
depletion and cell loss in the MPTP model [188]. The use
of creatine to increase levels of readily available ATP in
neurodegenerative diseases is promising. The results of a
large-scale clinical trial will further elucidate the potential of
its therapeutic eﬃcacy.
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6.3. SS Peptides. These small, synthetic peptide molecules
(named after their designers, Hazel Szeto and Peter Schiller)
have been utilised thanks to their ability to penetrate
numerous types of cells, including dopaminergic neurons,
despite carrying a +3 net charge [189]. Relevant to this
paper, is the ability of these peptides to enter mitochondria.
Evidence for the peptides’ capacity to do this began with
fluorescent labelling of a SS-02 analogue, which showed
colocalisation with a mitochondrial tracker as they concen-
trated at the inner mitochondrial membrane (IMM) within
isolated neurons [190]. This uptake occurs independently of
changes in mitochondrial transmembrane potential [191].
The mechanism behind this targeting is not known, but
it may be due to an electrostatic attraction between the
cationic peptides and the anionic cardiolipin molecules
which form in uniquely high density at the IMM [191]. As
mitochondrial potential can be diminished in disease states,
this membrane potential-independent uptake property may
be advantageous.
These mitochondria-targeting peptides have further neu-
roprotection weapons, including intrinsic dose-dependent
antioxidant properties. Peptides such as SS-02 and SS-
31 can scavenge hydrogen peroxide, hydroxyl radical, and
peroxynitrite by virtue of their tyrosine residue [190, 192].
This activity also inhibits lipid peroxidation. The localisation
of SS-02 and SS-31 to the IMM allows the peptides to
prevent mitochondrial swelling and depolarisation [190,
192], as shown in N2A neuroblastoma cells when depo-
larisation was induced by tert-butylhydroperoxide [193].
Specifically relevant to PD, SS-20 and SS-31 have been shown
to be protective in the MPTP mouse model [194]. The
latter peptide produced dose-dependent (0.1 to 10 mg/kg)
protection against SN dopaminergic neuronal loss and
maintained striatal levels of dopamine and its metabolites.
SS-20 also protected dopaminergic neurons against MPTP
insult, despite its lack of intrinsic ROS scavenging ability.
Both peptides were very potent in protecting cultured
neurons against MPP+-induced cell death, with eﬀectiveness
at nanomolar concentrations [194]. Impairment of oxygen
consumption, ATP depletion, and mitochondrial swelling
were all prevented by the peptides in isolated mitochondria
treated with MPP+ [194]. Brain uptake of MPP+ was not
altered in the in vivo study, showing that uptake mechanisms
were not altered by the peptides. Thus, the properties
outlined above such as ROS scavenging and prevention of
apoptosis may be utilised to prevent MPTP toxicity.
These peptides undoubtedly oﬀer a promising mito-
chondria-targeting treatment for PD. However, data so far
has come from one group, so although hitherto positive,
results should be treated with caution.
6.4. Natural Antioxidants. A number of naturally occurring
antioxidants has been shown to have protective eﬀects
against the degeneration induced by elevated ROS levels in
cases of mitochondrial dysfunction. There is great depth to
the number of potentially beneficial compounds which can
be derived naturally; for example, there has been over 4000
species of flavanoids, a group of established plant-derived
antioxidants, identified [195]. Green tea polyphenols (GTP)
have proven to be protective in SH-SY5Y cells against 6-
OHDA toxicity [196]. This group find an array of protec-
tive eﬀects initiated by GTP including prevention of the
decrease in mitochondrial membrane potential, suppressed
accumulation of ROS and a scavenging of free radicals in
a dose- and time-dependent manner. The eﬃcacy of the
green tea component (−)-epigallocatechin 3-gallate (EGCG)
has been demonstrated in the MPTP mouse model of
PD, with both loss of dopaminergic neurons and striatal
dopamine levels attenuated [197, 198] with the authors
suggesting that this protection is mediated by the inhibi-
tion of NOS expression. But the established antioxidant
properties of EGCG also supplement the neuroprotective
mechanism, as shown in a yeast-based α-synuclein model
in which EGCG, along with a further flavonoid, quercetin,
increased growth of α-synuclein cells though potent anti-
ROS and metal chelating mechanisms [199]. The route of
administration of these products is a great advantage of their
use, with the drinking of tea having beneficial eﬀects in
this study. Epidemiological evidence shows drinking more
than two cups a day of green tea has a protective eﬀect
against developing PD [200]. The abundance, accessibility,
and safety of this beneficial polyphenol make it attrac-
tive to study further as a potential clinical preventative
agent.
Oxyresveratrol (OXY), a polyphenol found in high
amounts in mulberry wood, has displayed potent scavenging
activity against reactive oxygen and nitrogen species in glial
cells after hydrogen peroxide exposure [201]. The compound
is also less cytotoxic to microglial cells than the antioxidant
resveratrol [201]. A study in 6-OHDA-treated neuroblas-
toma SH-SY5Y cells found OXY significantly reduced the
generation of ROS and attenuated apoptotic activities of
caspase-3 caused by impaired mitochondria [202]. Adding to
the previously realised protective eﬀect OXY has in cerebral
ischemia [203] and a profile of OXY as an eﬀective inhibitor
of apoptosis and oxidative stress in energy-deprived tissues is
becoming established.
Uric acid acts as an antioxidant, scavenging both reactive
oxygen and nitrogen species [204]. Epidemiological evidence
demonstrates a trend with higher uric acid serum levels cor-
relating with a lower incidence of PD [205–208]. It can also
protect against damage to mtDNA by intercepting radicals
[209], therefore helping to maintain mitochondrial genomic
integrity and prevent the induction of mutations. Uric
acid has been found to prevent dopaminergic cell death in
rotenone- and homocysteine-treated cells; treatments which
cause increased ROS production and exacerbated mito-
chondrial membrane depolarisation [210]. Guerreiro et al.
[211] proposes that uric acid neutralises oxygen species
via a Fenton-type chemical reaction, providing in vitro
dopaminergic neuroprotection. There is much positive data
regarding the antioxidative properties of uric acid, and
the ease that urate could be administered (i.e., by diet
supplementation) is a major advantage of this treatment.
However, the potential benefits of increasing urate levels
have to be balanced against the risk of developing gout and
cardiovascular problems [212]. Currently, participants are
being recruited to study the clinical safety of urate elevation
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in PD (SURE-PD) by dietary supplementation with inosine
[213].
Traditional herbal medicines may be eﬀective in attenu-
ating the accumulation of ROS in the event of mitochondrial
dysfunction. Cyperi rhizome (CR), the rhizome of Cyperus
rotundus, is a traditional herbal medicine used in Korea for
stomach disorders. A water extract of CR provided protec-
tion in vitro against 6-OHDA-induced toxicity through a
number of mechanisms including inhibition of both ROS
formation and mitochondrial membrane reduction in the
first study of the compound in a neurodegenerative disease
model [214]. Uncaria rhynchophylla is a herb that has been
used in Oriental medicine to treat hypertension, convulsions
and tremor. An extract has proven to be an eﬀective agent
against excitotoxicity in hippocampal slices [215]. However,
a study examining the antioxidant properties of a range
of extracts against lipopolysaccharide-induced NO release
found all but one of the 8 compounds tested displayed weak
NO inhibitory eﬀects only [216]. A form of this herb, the
hook of uncaria rhynchophylla (URH), has proven to be
protective in 6-OHDA-treated cells and lesioned rats [217].
In vitro, cell apoptosis and ROS levels were significantly
attenuated, while the rats showed reduced dopaminergic cell
loss. Further tests in other models may help further establish
this extract as an eﬀective antioxidant in the treatment of
mitochondrial disorders.
It may be necessary and desirable to look further at
this branch of antioxidant agents after the failure to slow
disease progression in clinical trials examining agents derived
from “modern medicine” [218, 219]. At present, however,
a lack of data in PD models (particularly when compared
to other neuroprotective agents discussed in the paper)
prevents the true potential and possible clinical value of these
antioxidants being comprehensively evaluated. Research of
these substances may become more widespread if putative
studies continue to deliver promising results.
7. Conclusion
The positioning and function of mitochondria make these
complex subcellular organelles uniquely susceptible to oxida-
tive damage, and impairment to their vital roles exacerbates
damage. Their placement at the centre of a plethora of
molecular pathways leads to activation of cell death and
apoptotic signal cascades, resulting in degeneration. Further
adding to the susceptibility of mitochondria is the presence
of their own DNA. The nature of this special genome means
that mutations are common, particularly in a structure
which routinely produces a baseline level of ROS with an
inadequate repair mechanism. These mutations accumulate
with age, which adds to the PD pathophysiology, since this is
a heavily age-related disorder. The use of several neurotoxins
as experimental models to reproduce many of the clinical
hallmarks of PD both in vitro and in vivo has allowed
the molecular mechanisms of the disease to be investigated
further. Common in all types of model is the dysfunction
which occurs in mitochondria, often through a direct block
of complex I in the electron transport chain, leading to
a cascade of further damage. Another milestone discovery
in PD research was the delineation of particular protein-
encoding genes which, when mutated, lead to the generation
of the Parkinsonian phenotype. These mutations are familial
in nature, lending subpopulations a degree of susceptibility.
The genes allowed further analysis of PD pathogenesis,
with mitochondrial dysfunction again proving a deleteri-
ous factor. Thus, impairment of these energy-producing
organelles provides a link between the common idiopathic
form of PD and the rare inherited form of the disease. This
makes mitochondria an attractive target for neuroprotective
strategies to halt neurodegeneration. Supplementation of
Coenzyme Q10 and creatine are methods which have proved
successful at pre-clinical level and have been tested in clinical
trials, with mixed results. Larger-scale clinical trials, using
the information found from previous studies in humans,
could help get the best out of these promising strategies.
The generation of small peptides, which possess many
properties desired in neuroprotective agents, have also shown
potential. Various natural antioxidants, including green tea
polyphenols, uric acid and extracts from Oriental herbs, have
shown potent antioxidant eﬀects, with some demonstrating
neuroprotective benefits in a bioenergetically challenged
environment, although relatively few studies of these sub-
stances in PD models have been carried out. The centring
of mitochondria in the pathogenesis of both idiopathic and
familial forms of PD mean further neuroprotective strategies
should target mitochondria, directly or indirectly, to counter
the deleterious and degenerating eﬀects that occur as a
consequence of their dysfunction. The ability of present
models to recreate mitochondrial impairment to such a
degree should allow this process to be tested vigorously and
with great accuracy in the laboratory before being presented
at the clinical stage.
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